Introduction
Positron emission tomography (PET) has become a prominent imaging modality in the field of oncology. 1 PET has several technical advantages over the single photon emission computed tomography (SPECT) like attenuation correction, and higher spatial resolution. [2] [3] Small molecules such as sugars, amino acids, nucleic acids, or receptor-binding ligands are labeled with positron-emitting radionuclides for PET imaging to study in vivo visualization of physiological processes on a molecular level. [4] [5] [6] [7] There are several positron emitting radionuclides like fluorine- 18 In recent years, Gallium-68 [
68 Ga] -a positron emitting radionuclide conveniently available in the form of Germanium-68 (t1/2 ≈ 270 days)-Gallium-68 (t1/2 ≈ 68 min) [ 68 
Ge
68 Ga] generator has drawn considerable attention for oncologic diagnostic applications. The short physical halflife of 68 Ga induces low radiation burden on patients and makes it an ideal radionuclide for diagnostic use. [8] [9] [10] The labeling of biomolecules with 68 Ga is achieved by using bi-functional chelators (BFC) such as DTPA (diethylene triamine pentaacetic acid), DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid), NOTA (1,4,7-triazacyclononane-1,4,7-triacetic acid), or NODAGA (1,4,7-triazacyclononane-1-glutamic acid-4,7-diacetic acid). BFCs differ from each other in their physio-chemical properties which can influence radiolabeling kinetics. They can also influence overall charge of the complex, biodistribution and more importantly uptake in the tumor site. [11] [12] [13] In recent years, there has been increasing interest in the receptor targeted scintigraphy in which peptides have emerged as promising biomolecules.
14 Their properties such as fast clearance, rapid tissue penetration, low antigenicity, and relatively easy synthesis have added to their applicability. 15 In past few years, our laboratory has designed, synthesized and radiolabeled peptide conjugates which have high affinity for VPAC-1 receptors, over-expressed in many malignant tumors including those of the breast and prostate. [16] [17] [18] [19] [20] The peptides are analogues of Pituitary adenylate cyclase-activating peptide (PACAP) -a 27 amino acid peptide and vasoactive intestinal peptide (VIP)-28 amino acid. Both have similar biochemical properties and bind to VPAC1 receptors expressed in high density on the surface of certain cancers such as of the breast, prostate and urinary bladder (100%), colon (96%), pancreas (65%), lung (58%), stomach (54%), and liver (49%). [21] [22] [23] [24] The present study was aimed to investigate the influence of these two BFC agents on the PACAP analogue, which differs in terms of their radiolabeling kinetics, biological activity and stability of the resultant product.
Methods and materials

Reagents
Fmoc amino acid, solvents and reagents for peptide chelator synthesis, was purchased from Fluka Chemicals (St. Louis, MO). The BFC DOTA was purchased from Macrocyclics (Dallas, TX) and NODAGA was purchased from Chematech (Dijon, France). Sodium acetate, diethylenetriamine pentaacetic acid (DTPA), calcium chloride (CaCl2), zinc chloride (ZnCl2), Ferric chloride (FeCl3), hydrochloric acid solutions were purchased from Fisher Scientific, Inc. (Waltham, MA). Transferrin was purchased from Sigma-Aldrich (St. Louis, MO). A 370MBq [68Ge-68Ga] generator was purchased from Eckert and Zeigler (Berlin, Germany). Sodium chloride solution (0.9%) was prepared in this laboratory using deionized water. Human serum was prepared from whole blood drawn from a volunteer. All chemicals were used without further purification.
Instruments
Peptide was purified using a preparative column on high-pressure liquid chromatography (HPLC) system (Shimadzu Corporation, Kyoto, Japan) equipped with gradient pumps and UV/VIS detector, a NaI(Tl) radioactivity monitor, and a rate meter. The reverse phase C18 microbound column (4.6 mm × 250 mm) served as the stationary phase, and two solvents: 0.1% Trifluoroacetic acid (TFA) in H2O and 0.1% TFA in acetonitrile as mobile phase. The gradient was such that 10% CH3CN in aqueous 0.1% CF3COOH to 100% CH3CN in 0.1% CF3COOH at a flow rate of 1 mL/min over 28 min at 22°C. For thin layer chromatography (TLC), pre-coated aluminum sheets with silica gel were purchased from Merck (Kenilworth, NJ) and radioactivity was measured on Perkin Elmer 2480 wizard 2 automatic gamma counter (Waltham, MA). The pH of the solutions was measured using either a pH meter (Sartorius, Gottingen, Germany) or pH strips (Fisher scientific Inc.)
Synthesis of peptide conjugate
Briefly, the PACAP analogue with C-terminal NODAGA/DOTA chelators was synthesized on a Wang resin using an ABI 341A peptide synthesizer (Applied Biosystems, Foster City, CA). Fmoc-Lys (ivDde) was first introduced at the C terminus of the peptide, followed by 4-aminobutyric acid (y-Aba). The 27-amino-acid-long PACAP sequence was then assembled by standard Fmoc coupling with the final histidyl residue, being a t-Boc-protected His(Trt) derivative. The capping t-Boc function was necessary to ensure that the N-terminal amino group remained protected during subsequent deprotection and coupling cycles performed at the c amino group of the Cterminal lysine. The ivDde group at the C-terminal lysine was then selectively removed with 2% hydrazine, followed by coupling with DOTA or NODAGA. The peptide was cleaved from the resin using TFA/water/ phenol/thioanisole/ethanedithiol (82.5:5:5:5:2.5) and precipitated with diethyl ether. The crude peptide was purified to homogeneity by reversed phase HPLC using a preparative column. The peptide was characterized by matrix-assisted laser desorption/ionization-time of flight (MALDI-TOF) mass spectrometry.
Radiolabeling
For radiolabeling, 300 µL (14.5 -18.5 MBq) of 68 GaCl3 was added in a clean glass test tube to which were added varying amounts of acetate buffer to study the influence of pH (1.0 -6.0) and varying amount of a 4 mg/mL peptide-chelators water solution (1-20 µg). The mixture was heated at predetermined temperatures (25, 50, 70 and 90 °C) for pre chosen time periods (10, 15, 20 and 30 min) to study the kinetics of the radiolabeling reactions with respect to temperature and time. The radiolabeling was evaluated by Radio-HPLC.
Preparation of free
68 GaCl3, 68 Ga-hydrolyzed, 68 Ga-DTPA and 68 
Ga-Tf as reference standard
To identify HPLC peaks of the 68 Ga species, HPLC peaks, that may have formed during the chelation experiments, free 68 GaCl3 (as eluted from generator with 0.1M HCl), 68 Gahydrolyzed products, 68 Ga-DTPA and 68 Ga-Transferrin (Tf) were prepared as described [25] [26] 13 and their retention times were recorded on radio-HPLC.
Stability (in vitro), transchelation and transmetallation studies
For the stability, transchelation and transmetallation studies, 68 Ga-peptide-chelators were prepared by mixing 300 µL (14.5 -18.5 MBq) of 68 GaCl3 in 0.1 M HCl, 120 µL of 1.0 M sodium acetate and 5 µL (20 µg) of peptide-chelators. The preparation was incubated at 90°C for 30 min. Aliquots of 68 Ga-peptide-chelators solutions (0.3 mL, approx. 15 MBq) were alternatively mixed with (1) 0.3 mL of a 0.9% NaCl, (2) 0.3 mL of a 100 nM Fe 3+ /Zn 2+ /Ca 2+ (for transmetallation study), (3) 0.3 mL of a 200 μM DTPA solution, (4) 0.3 mL of a 50 μM transferrin solution (for transchelation study) and (5) 0.3 mL of human serum solution. The mixtures were incubated at 37 °C and analyzed after 0, 10, 30, 60 and 120 min of incubation, respectively. A 10 μl (in 100µL of normal saline) aliquot preparations of (1), (2) and (3) were injected in the radio-HPLC while preparations (4, 5) were analyzed by ITLC-SG using 0.1M citric acid as a solvent.
Cell binding (in vitro) assay
Estrogen receptor-positive T47D human breast tumor cells from American Type Culture Collection were maintained in RPMI 1640 medium with 2 mM L-glutamine contained 10 mM HEPES, 1.0 mM sodium pyruvate, 1.5 g/L sodium bicarbonate, 4.5 g/L glucose and supplemented with 0.2 Units/ml 90 %bovine insulin, and 10% fetal bovine serum, at 37°C under 5% CO2/95% air. The cells when confluent were detached using 0.25% trypsin-EDTA, washed and resuspended with RPMI-1640 medium at a concentration of ~ 5× 10 6 cells/mL. Each test tube contained 1 mL of cell suspension into which 10 µL of 68 Ga-peptide-chelator (approx. 0.74 MBq) was added and incubated for 2 hr at 37°C in a water bath. The incubation was terminated by adding 0.5 ml of cold normal saline. The mixture was centrifuged at 3000 rpm for 10 minutes. The supernatant from each wash was collected into marked test tubes. To the remaining pellet, 1.0 ml of normal saline was added and centrifuged again at 3000 rpm for 10 minutes. The supernatant was separated and collected in the marked test tube. The cells and supernatant were counted for radioactivity in a gamma counter and percentage of radioactivity bound on the cells was calculated.
Biodistribution studies
The biodistribution of 68 Ga labeled peptide was studied in normal (n = 10, athymic nude, female mice, 20-25 g). The resultant optimal preparation procedure was used which contained 300 µL of Ga-peptide (3.7 -5.5 MBq) was administered intravenously through a lateral tail vein in 200 µL of the preparation (pH ≈ 5.5). Radioactivity in the syringe before and after administration was measured in an energy-calibrated dose calibrator (CRC-15; Capintec, Ramssey, NJ), and the exact quantity received by each animal was determined. A standard 68 GaCl3 solution of a known quantity was prepared at the time of injection. The animals (n = 5, each study) were sacrificed at 1 h post injection by CO2 inhalation. Various organs were removed, washed free of blood, blotted dry, and weighed. The associated radioactivity was counted in the γ-counter and results were calculated as percentage injected dose per gram (% ID/g) of tissue.
Results
Purity of peptide-chelators conjugates
NODAGA-and DOTA-peptide purity as determined by HPLC was 99%. The MALDI-TOF demonstrated that, for NODAGA-peptide observed molecular mass was 3716 (calculated molecular mass-3718) whereas for DOTA-peptide observed molecular weight was 3787 (calculated molecular mass-3785). The MALDI peaks for the peptide conjugates are given in Figure 1A and B.
Radiolabeling kinetics
Optimal radiolabeling (> 95.0%) of the DOTA-conjugated peptide required pH 2-5 and higher (50-90ºC) temperature, while the NODAGA conjugated peptide needed incubation only at room temperature at same pH range. At higher temperature (90°C), the radiolabeling was not affected by pH for both peptide conjugates ( Fig. 2A, B ) and can be labeled at wide range of pH (1.0 -6.0). NODAGA-peptide can bind 68 Ga at a minimal quantity of 1 µg but DOTA-peptide required minimum of 20 µg to yield optimal (≥ 95%) radiolabeling (Fig. 2C) . The minimum incubation time needed for optimal (> 95%) radiolabeling was 10 minutes at 90°C (Fig. 2D) . Radio-HPLC showed retention time for both radio-complexes was 9.9 ± 0.3 minutes as compared to 3.1 ± 0.2 minutes for free 68 Ga as shown in Fig. 3-b . The retention time was also determined for the reference standard like hydrolyzed 68 GaCl3, 68 Ga-DTPA and 68 Ga-transferrin and found to be 3.5 ± 0.2 minutes.
Stability studies
Both
68 Ga labeled peptide conjugates were stable in 0.9% normal saline (Fig. 4A ) and showed minimal (1-2%) degradation against (FeCl3, CaCl2 and ZnCl2) transmetallation (Fig. 4B-D) up to 2 hours. The transchelation study with DTPA (Fig. 5A) and transferrin (Fig. 5B ) solution showed that both radio-complexes were remained intact over 2 hours. Radio-TLC showed ratio factor (Rf) value of 0.0-0.1 for 68 Ga labeled peptide and 0.9-1.0 for free 68 GaCl3..
Cell binding (in vitro) assay
Cell binding assay showed higher uptake for 68 Ga-NODAGA-peptide, 34.0% ± 0.8% as compared with 24.5% ± 0.9% for 68 Ga-DOTA-peptide at 15 minutes. However, at 2 hours of incubation at 37ºC, the uptake was nearly same, 48.9% ± 3.9% for 68 Ga-NODAGA-peptide and 45.2% ± 2.1% for 68 Ga-DOTA-peptide (Table -I ).
Biodistribution studies
The biodistribution pattern of the both 68 Ga labeled peptide conjugate is shown in Figure  6 . In both cases, a higher uptake is seen in kidneys followed by liver, blood and lungs. It was evident that the 68 Ga-NODAGA-Peptide showed rapid blood clearance as compared to 68 Ga-DOTA-peptide. Liver uptake was 8.8% for 68 Ga-NODAGA-Peptide was lower (p = 0.01) as compared to 16.5% for 68 Ga-DOTA-peptide. Most of the activity was excreted through kidney.
Discussion
With its several advantages such as the availability in a generator form, cyclotron independency, multi elution ability in a single day, simplified radiolabeling chemistry with several biomolecules using bifunctional chelating agents, the use of 68 GaCl3 is rapidly growing for diversified clinical applications. 27 The presence of even µg levels of metallic impurities (with ageing of generator) in 68 GaCl3 or reagent used may hamper the radiolabeling complexation. The removal of radionuclide impurities however has helped expansion of its use for clinical application. 28 The eluate of 68 GaCl3 from the generator may contain metal ion impurities such as Fe 3+ , Cu 2+ , Al 3+ , Zn 2+ and Sn 4+ which could hamper the radiolabeling of biomolecules. It is important therefore to identify the suitable chelating agent for the radiolabeling which is least affected by these impurities as well the stability of the labeled compound. [29] [30] DOTA is the most commonly used chelating agent and 68 Ga-DOTATOC is accepted in the European Pharmacopeia. 31 68 Ga labeled DOTA biomolecules conjugates (like peptides, antibody, and small molecules) have been successfully developed and used for many clinical applications. The disadvantage of DOTA conjugate is its slow reaction kinetics for complex formation with 68 Ga. 32 These limitations prompted us to investigate the use of NODAGA for comparison with DOTA.
Chelator-peptide conjugates were synthesized by solid phase peptide synthesis method. Both peptide conjugates were synthesized with high purity (~ 99.0%). NODAGApeptide conjugate showed faster kinetics as compare to DOTA-peptide conjugate and less influenced by the pH variation. NODAGA peptide conjugate yielded higher radiolabeling efficiency at minimal quantity of peptide (1 µg), at room temperature and within short incubation (5 min) time. For the preparations with short lived radionuclides like 68 Ga, these characteristics of NODAGA are advantageous. The faster radiolabeling kinetics may be attributable to its ionic size compatibility with cavity size of the nine membered triazomacrocycle of NODAGA and therefore, yielding a high radiolabeling in 5 min at room temperature. 33 A low radiolabeling was observed in acidic (pH-1.0) conditions for both peptide conjugates when incubated at temperature (25-70°C) . It may attribute to strongly acidic environment which might have protonated the donor atoms of the ligand and destabilized the 68 Ga complex. 34 At high temperature (~ 90°C), the radiolabeling was found to be independent of pH variation (Fig. 2 a-b) . However at pH 7.0 and above, labeling decreases (data not included). This may be due to a fact that at acidic pH, 68 Ga remains predominant in cation Ga 3+ form (> 90%), though soluble complex ions Ga(OH) 2+ , Ga(OH) + 2 may be present in the solution. As the pH of the solution shifts towards basic (> 7.0), the hydrolyzed form of Gallium, Ga(OH) -4 increases and decreases the radiolabeling yield. 35 Once the peptide conjugate is radiolabeled, then adjusting the pH to physiological pH 7.0 does not adversely influence the chelated Ga-68.
The use of sodium acetate buffer maintained the pH and allowed strong formation BFC-68 Ga complex. The other advantage of using sodium acetate buffer is its biocompatibility for human use. 36 DOTA peptide conjugate showed labeling at high temperature. Therefore, DOTA may not be useful for those peptides which can denature at higher temperature and become unsuitable for molecular imaging. On the other hand, radiolabeling of NODAGA-peptide at room temperature ruled out major thermal denaturation. Radio-HPLC showed that the formation of the 68 Ga-NODAGA and DOTA peptide conjugate has retention time of around 9.9 min whereas free 68 Ga eluted at 3.6 min ( Fig. 3-b) and complex formation between 68 Ga and NODAGA-peptide conjugate is shown in Fig. 3 -a . HPLC UV detector also detected the UV peak for NODAGA and DOTA peptide conjugate at around 9.9 min. Therefore, it confirmed the complexation of the 68 Ga with peptide conjugate which leads to the retention of the 68 Ga labeled peptide approximately at the same time.
Both radio-complexes were found to be stable in normal saline (Fig. 4a) and human serum over 120 minute. The stability in human serum (at 37°C) indicated its suitability for in vivo applications and showed their inertness towards the metal ion/species that may be present in the serum. The transmetallation study was important not because these ions are present as impurities in the eluate but these ions are also present in serum in appreciable quantity. 37 68 Ga-NODAGA and DOTA peptide conjugates showed minimal (1-2%) degradation in radiolabeling after 120 minute incubation with respective ion solution at 37°C (Fig. 4-b-d ). This could also provide an indication about the stability of these radio-complexes in in vivo environment. Transferrin is the major protein in the plasma which is known to form a strong complex with 67 Ga-citrate. 38 The minimal transchelation (~1-2%) of 68 Ga-peptide conjugates with transferrin showed the stability of radio-complexation (Fig. 5-a-b) .
The cell binding assay was performed on T47D breast cancer lines which express VPAC-1 receptors on their surface.
19 68 Ga-NODAGA-peptide showed higher uptake in 15 minute as compared to 68 Ga-DOTA-peptide but the uptake was almost same at 2hr (Table-1 ) which may be due to saturation of the receptor site. The biodistribution data (Fig. 6) showed that both radio-complexes were cleared through kidneys. Hence, renal system was the major route of clearance from the body.
68 Ga-NODAGA-peptide was cleared rapidly form the blood and had significantly less liver uptake (p < 0.05) as compare to 68 Ga-DOTA-peptide at 1 hr. The fast clearance from the blood may be advantageous in reducing the background radioactivity for PET imaging but it could also limit the accumulation of radioactivity at target (tumor) area. Hence, a detailed in vivo investigation will be required further for any conclusion.
In the present study, we have showed that 68 Ga-NODAGA-peptide exhibited most favorable features from radiochemistry point of view. Chelator NODAGA has flexibility over the influence of temperature and acidic environment. 13 Labeling at room temperature provides an advantage and could prevent any deleterious effect on peptide conjugate due to heating. Both peptide conjugates were found to be stable in serum, against transchelation and transmetallation experimentations. A detailed in vivo study is in progress to investigate the influence of chelators on the biodistribution and tumor targeting.
Conclusions
A comparison between NODAGA and DOTA revealed that NODAGA-peptide conjugate could be efficiently radiolabeled with 68 Ga at room temperature with high yield. 68 Ga-NODAGA-peptide conjugate remained stable in serum, in presence of major metal ions impurities, against transchelation with DTPA or transferrin. The biodistribution data showed its clearance from kidneys, which minimize the radiation burden on the organs. The clearance of 68 Ga-NODAGA-peptide from blood was faster as compare to 68 Ga-DOTA-peptide and would be advantageous for PET imaging.
